abstract |
The present invention provides human antibodies or functional fragments thereof that target HCV E2 glycoprotein and retain neutralizing activity in vivo; An anti-HCV therapy composition containing a therapeutically effective amount of the antibody; Topical compositions as gels, creams, ointments, antiseptics; It relates to the use of such antibodies to validate anti-HCV vaccines. |